Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome

Launched by ASOCIACIÓN PARA EVITAR LA CEGUERA EN MÉXICO · Jun 29, 2006

Keywords

ClinConnect Summary

This clinical trial is looking at a new treatment for a condition called retinopathy of prematurity (ROP), which can cause vision problems and blindness in premature babies. The study is testing a medication called bevacizumab, which is delivered directly into the eye, to see if it can safely help prevent the growth of abnormal blood vessels that can damage vision in babies with advanced stages of ROP. Traditional treatments like laser therapy don't always result in good vision outcomes, so researchers hope that this new approach can offer better results.

To be eligible for this trial, babies aged between 30 days and 1 year who have ROP stages III, IV, or V and cannot be treated with laser or cryotherapy can participate. Unfortunately, if a baby can be treated with those conventional methods, they will not be included in the study. Parents of participating infants can expect close monitoring and support throughout the trial to ensure their child's safety and well-being. The goal is to find out if this new treatment can improve vision outcomes for vulnerable babies with this serious condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Retinopathy of prematurity stages III, IV and V in which we can not treat with laser o cryotherAPY
• Exclusion Criteria:
• • PATIENTS THAT COULD BE TREATED WITH CRYOTHERAPY OR LASER